+49 89 8103 9100

What we do

We are a clinical-stage biopharmaceutical company developing protein therapeutics for the treatment of diseases with serious unmet need, primarily cancer. We were founded in 2001 by scientists of the Max-Planck Institute of Biochemistry and in 2008 became a member of the Daiichi Sankyo Group, one of the leading pharmaceutical companies worldwide.

Small Team

We are small. We are large.

Medical breakthroughs seldom arise from large teams of scientists. But from the expertise and passion of a few outstanding minds.

Accordingly, we have established a small, effective team. The group is made up of brilliant, passionate research scientists who can understand you precisely and speak your language. Your contact person is also a decision-maker, and decisions are made quickly and feedback is given promptly when there are only 40 members of staff.

We are small, yet, if required, we can also be large – with enormous capacities.

Great Potential

We are large. We are small.

Next to great minds, the development of outstanding, innovative drugs for the treatment of serious illnesses also requires a completely different kind of resource: money. With the international Daiichi Sankyo Group, which has 17,000 employees and European Headquarters in Munich, we have accumulative power and additional experience and expertise on our side.

In spite of all this, you will not notice anything as, in your eyes, we will remain a straightforward, approachable team with a designated contact person. But you will notice it when you actually bring your innovation onto the market: because you will need endurance and staying power – to take every chance and opportunity.


Who understands scientists better than scientists?

Our key foundation: passion.

Professor Axel Ullrich, Director, Max Planck Institute of Biochemistry, founded the company U3 Pharma in 2001. Since its formation, U3 Pharma has been ignited by the passion to spearhead and drive forward the area of target medicines aimed at combating cancer.

The business works in close cooperation with several leading academic institutions and is constantly forming new contacts and partnerships with the international research community.

U3 Pharma is currently employing 39 staff members, including 15 people with a doctorate.

About Us!

Target Evaluation

Lead Generation


Phase I

Phase II

Phase III

Patritumab (anti-HER3)
U3-1565 (anti-HB-EGF)
U3-1784 (Antibody)
U3-1402 (ADC)
U3-120 (Antibody)
U3-191 (ADC)
U3-808 (Antibody)
U3-771 (Antibody)

Progress – accelerated.

Our leading research position is no accident. The groundbreaking discoveries of our founder and the Director of the Max Planck Institute in Munich, Professor Axel Ullrich, provided an excellent foundation. Leading brains are now developing our prominence further.

Our acute understanding of target biology on one side, along with our parallel screening for hits on the other side, quickly and emphatically advances our research into highly efficient active ingredients.

Our scientific focus is based around the discovery and development of revolutionary drugs that offer the maximum benefits for patients, especially against cancer.

Through our partnership with the international player Daiichi Sankyo we also have all the necessary means available to us.

+ more


We collaborate extensively with academic groups for the initiation and progression of our projects and we are keenly aware that basic research is the start of every drug development. If you would like to collaborate with U3 Pharma, please contact us.

Contact us!

A selection of our partners

Discover your market potential now.

Briefly describe your discovery to us. We would be pleased to respond to you promptly regarding the potential for implementing your discovery.

Simply contact us by e-mail, telephone or fax. We look forward to hearing from you.

Naturally, we are also available to respond to any other queries.

U3 Pharma GmbH
Fraunhoferstr. 22
82152 Martinsried

Tel +49 89 8103 9100
Fax +49 89 8103 9199

An active ingredient does only have an impact, when it comes on the market.

The discovery of a new drug candidate is like an inner moment of realisation. A unique, emotional moment. We understand this feeling because we have experienced it ourselves on several occasions.

Only: How do you arrange for a drug candidate to receive clinical development and then be released onto the market? How can it help people and bring real value?

As drivers of biomedical progress, we know exactly what is required to successfully bridge this ‘Valley of Death’ towards market entry. Many years of experience and scientific excellence are indispensable for this purpose. And, in addition, there is the immense potential that comes from partnering with one of the world’s largest pharmaceutical groups as a backdrop.